Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Somatostatin and cancer

R J Robbins1

  • 1Department of Endocrinology and Metabolism, Cornell University Medical College, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Metabolism: Clinical and Experimental
|August 1, 1996
PubMed
Summary

Somatostatin (SRIF) shows potential in nonendocrine cancer diagnosis and treatment by inhibiting tumor growth. SRIF analogs may aid in imaging and therapy, but further research is needed to confirm efficacy in human cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of hydroxycinnamic acids on blue color expression of cyanidin derivatives and their metal chelates.

Food chemistry·2017
Same author

Spectral and colorimetric characteristics of metal chelates of acylated cyanidin derivatives.

Food chemistry·2016
Same author

Evaluating the role of metal ions in the bathochromic and hyperchromic responses of cyanidin derivatives in acidic and alkaline pH.

Food chemistry·2016
Same author

Recent advances in the management of adrenal incidentalomas.

Trends in endocrinology and metabolism: TEM·2008
Same author

Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2004
Same author

Giant-cell granulomatous hypophysitis.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2004

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Somatostatin (SRIF) exhibits growth-inhibitory effects on normal and cancerous cells in vitro.
  • Somatostatin receptors (ssts) are expressed on numerous human cancers, suggesting a role in regulating proliferation.

Purpose of the Study:

  • To review the potential applications of somatostatin (SRIF) and its analogs in the diagnosis and treatment of nonendocrine human cancers.
  • To explore the mechanisms and clinical utility of SRIF in oncology.

Main Methods:

  • Review of existing literature on SRIF, somatostatin receptors (ssts), and their role in cancer.
  • Discussion of diagnostic imaging techniques using radiolabeled SRIF analogs (e.g., PET).
  • Exploration of therapeutic strategies involving SRIF analogs, including direct and indirect effects.

Main Results:

  • SRIF and its analogs demonstrate in vitro growth inhibition of cancer cells.
  • SRIF analogs can be used for tumor imaging via radiolabeled tracers and potentially for targeted radiation delivery.
  • Clinical benefits observed in cancer patients may stem from indirect effects like pain relief and reduced chemotherapy side effects.

Conclusions:

  • SRIF analogs hold promise for cancer diagnosis and as adjuncts in therapy, particularly for imaging and potentially delivering targeted radiation.
  • Further investigation into sst subtypes and intracellular SRIF signaling is crucial for optimizing therapeutic strategies.
  • SRIF analogs are likely to be most effective when used in combination with established cancer treatments.

Related Experiment Videos